Sign Up
OverviewAPI
The Biden administration's Medicare drug price negotiations will face major tests in 2024, potentially affecting senior patients and the pharmaceutical industry. The negotiations aim to make prescription drugs more affordable for older Americans and have significant implications for drug pricing and industry profits. Legal challenges by drugmakers against the price talks are also expected.

Ask a question